First generic version of Xeloda (capecitabine) has been approved by U.S. Food and Drug Administration (FDA). Xeloda is already approved for the treatment of patients suffering from metastatic breast and colorectal cancer.
“Generic drugs are important options that allow greater access to health care for all Americans,” said Kathleen Uhl, M.D., acting director of the Office of Generic Drugs in the FDA’s Center for Drug Evaluation and Research. “This medication is widely used by people living with cancer, so it is important to have access to affordable treatment options.”
According to the national cancer institute, nearly 1.6 million will suffer and approximately 580,000 patients will die due to cancer in United State in 2013. Following table shows the data of patients that will suffer and die due to different types of cancer in 2013.
Table 1: Expected rate of mortality and morbidity in the year 2013.
|Type of cancer||Expected diagnosis||Expected deaths||
The common side effects associated with the use of Xeloda include;
- Mouth sores
- Hand and foot syndrome and etc.
Source: FDA News Release
Copyright 2012 Medimoon.com. All rights reserved. No part of this site can be reproduced without our written permission.None found.